Clinical Trials Directory

Trials / Unknown

UnknownNCT04466085

Clinical Study of Recombinant Novel Coronavirus Vaccine

A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
900 (actual)
Sponsor
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Industry
Sex
All
Age
18 Years – 59 Years
Healthy volunteers
Accepted

Summary

A total of 900 subjects are planned to be randomly divided into 2 doses of low-dose experimental vaccine group, 2 doses of high-dose experimental vaccine group, 2 doses of placebo group, 3 doses of low-dose experimental vaccine group, 3 doses of high-dose experimental vaccine group and 3 doses of placebo group, the sample size of each group was 150 cases.

Detailed description

A total of 900 subjects are planned to be randomly divided into 2 doses of low-dose experimental vaccine group, 2 doses of high-dose experimental vaccine group, 2 doses of placebo group, 3 doses of low-dose experimental vaccine group, 3 doses of high-dose experimental vaccine group and 3 doses of placebo group, the sample size of each group was 150 cases. Subjects in the 2 dose group were injected with 2 doses of test vaccine or placebo in the upper arm deltoid muscle according to the 0,1 month immunization program, and subjects in the 3 dose group were injected with 3 doses of test vaccine or placebo in the upper arm deltoid muscle according to the 0, 1, 2 month immunization program .

Conditions

Interventions

TypeNameDescription
BIOLOGICALRecombinant new coronavirus vaccine (CHO cell) low-dose groupIntramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
BIOLOGICALRecombinant new coronavirus vaccine (CHO cells) high-dose groupIntramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
BIOLOGICALRecombinant new coronavirus vaccine (CHO cells) placebo groupIntramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).

Timeline

Start date
2020-07-12
Primary completion
2020-10-22
Completion
2021-12-15
First posted
2020-07-10
Last updated
2020-12-03

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04466085. Inclusion in this directory is not an endorsement.